HUP0100302A3 - Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds - Google Patents

Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds

Info

Publication number
HUP0100302A3
HUP0100302A3 HU0100302A HUP0100302A HUP0100302A3 HU P0100302 A3 HUP0100302 A3 HU P0100302A3 HU 0100302 A HU0100302 A HU 0100302A HU P0100302 A HUP0100302 A HU P0100302A HU P0100302 A3 HUP0100302 A3 HU P0100302A3
Authority
HU
Hungary
Prior art keywords
azaquinoxaline
methods
protein kinase
based compounds
threonine protein
Prior art date
Application number
HU0100302A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HUP0100302A2 publication Critical patent/HUP0100302A2/hu
Publication of HUP0100302A3 publication Critical patent/HUP0100302A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0100302A 1997-10-06 1998-10-05 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds HUP0100302A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6112397P 1997-10-06 1997-10-06
PCT/US1998/020910 WO1999017759A2 (en) 1997-10-06 1998-10-05 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds

Publications (2)

Publication Number Publication Date
HUP0100302A2 HUP0100302A2 (hu) 2001-06-28
HUP0100302A3 true HUP0100302A3 (en) 2006-03-28

Family

ID=22033733

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100302A HUP0100302A3 (en) 1997-10-06 1998-10-05 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds

Country Status (31)

Country Link
US (2) US6180631B1 (hu)
EP (1) EP1028729B1 (hu)
JP (1) JP2001518496A (hu)
KR (1) KR100633270B1 (hu)
CN (1) CN1169527C (hu)
AR (1) AR013542A1 (hu)
AT (1) ATE336250T1 (hu)
AU (1) AU757585B2 (hu)
BG (1) BG64969B1 (hu)
BR (1) BR9814814A (hu)
CA (1) CA2306257C (hu)
CY (1) CY1106223T1 (hu)
CZ (1) CZ298775B6 (hu)
DE (1) DE69835612T2 (hu)
DK (1) DK1028729T3 (hu)
ES (1) ES2268791T3 (hu)
HK (1) HK1031836A1 (hu)
HU (1) HUP0100302A3 (hu)
IL (2) IL135103A0 (hu)
MX (1) MXPA03011007A (hu)
NO (1) NO316598B1 (hu)
NZ (1) NZ503431A (hu)
PL (1) PL192039B1 (hu)
PT (1) PT1028729E (hu)
RU (1) RU2223753C2 (hu)
SK (1) SK4722000A3 (hu)
TR (2) TR200000906T2 (hu)
TW (1) TWI245765B (hu)
UA (1) UA71555C2 (hu)
WO (1) WO1999017759A2 (hu)
ZA (1) ZA988961B (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
JP2002534468A (ja) * 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
EP2324825A1 (en) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
US20040131504A1 (en) * 2002-09-17 2004-07-08 Landers James P. Remote temperature sensing of small volume and related apparatus thereof
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ATE366108T1 (de) * 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
BRPI0410633A (pt) * 2003-05-23 2006-06-13 Zentaris Gmbh piridopirazinas e uso das mesmas como moduladores de cinase
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
CA2529090A1 (en) * 2003-06-13 2004-12-23 Novartis Ag 2-aminopyrimidine derivatives as raf kinase inhibitors
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
KR101400905B1 (ko) * 2005-11-11 2014-05-29 아에테르나 젠타리스 게엠베하 신규한 피리도피라진 및 키나제의 조절제로서의 이의 용도
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2010003308A1 (zh) * 2008-07-10 2010-01-14 卞化石 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
CN104903320B (zh) * 2013-01-11 2018-11-13 富士胶片株式会社 含氮杂环化合物或其盐
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JP6980385B2 (ja) 2014-03-26 2021-12-15 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
DK3174868T3 (da) 2014-08-01 2021-11-08 Nuevolution As Forbindelser, der er aktive mod bromodomæner
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
US20190256492A1 (en) * 2018-02-19 2019-08-22 Washington University Alpha-synuclein ligands

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001017A (en) * 1972-12-05 1977-01-04 Ciba-Geigy Ag Process for the photopolymerization of ethylenically unsaturated compounds
US4043819A (en) * 1974-06-11 1977-08-23 Ciba-Geigy Ag Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
FR2656606B1 (fr) * 1989-12-28 1993-06-25 Roussel Uclaf Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure.
CA2078214C (en) 1990-04-02 1995-03-28 Robert Lee Dow Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
RU2155187C2 (ru) 1992-08-06 2000-08-27 Варнер-Ламберт Компани Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase

Also Published As

Publication number Publication date
IL135103A (en) 2007-06-17
MXPA03011007A (es) 2004-02-27
ES2268791T3 (es) 2007-03-16
WO1999017759A2 (en) 1999-04-15
PT1028729E (pt) 2006-12-29
AR013542A1 (es) 2000-12-27
HK1031836A1 (en) 2001-06-29
PL192039B1 (pl) 2006-08-31
CA2306257A1 (en) 1999-04-15
CA2306257C (en) 2007-09-25
ZA988961B (en) 1999-10-04
NO20001748D0 (no) 2000-04-05
SK4722000A3 (en) 2002-06-04
US6727252B1 (en) 2004-04-27
KR100633270B1 (ko) 2006-10-16
TR200000906T2 (tr) 2000-11-21
RU2223753C2 (ru) 2004-02-20
EP1028729A2 (en) 2000-08-23
DE69835612T2 (de) 2007-08-16
IL135103A0 (en) 2001-05-20
ATE336250T1 (de) 2006-09-15
EP1028729B1 (en) 2006-08-16
CN1274284A (zh) 2000-11-22
BG104392A (en) 2000-12-29
US6180631B1 (en) 2001-01-30
CN1169527C (zh) 2004-10-06
AU9514198A (en) 1999-04-27
CZ20001129A3 (cs) 2000-10-11
DK1028729T3 (da) 2006-12-11
JP2001518496A (ja) 2001-10-16
NO20001748L (no) 2000-04-05
PL339860A1 (en) 2001-01-15
TR200100385T2 (tr) 2002-06-21
AU757585B2 (en) 2003-02-27
HUP0100302A2 (hu) 2001-06-28
WO1999017759A3 (en) 2000-01-06
NO316598B1 (no) 2004-03-01
CZ298775B6 (cs) 2008-01-23
BG64969B1 (bg) 2006-11-30
CY1106223T1 (el) 2011-06-08
NZ503431A (en) 2002-07-26
UA71555C2 (en) 2004-12-15
TWI245765B (en) 2005-12-21
KR20010030934A (ko) 2001-04-16
DE69835612D1 (de) 2006-09-28
BR9814814A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
HUP0100302A3 (en) Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds
ZA988797B (en) Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds.
AU7282998A (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
AU3363599A (en) Heterocyclic families of compounds for the modulation of tyrosine protein kinase
HUS1600018I1 (hu) Aril kondenzált azapoliciklusos vegyületek
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
PL340727A1 (en) Benzothiazolic inhibitors of proteinous thyrosinic kinase
AU3766897A (en) Fused heterocyclic compounds as protein tyrosine kinase inhibitors
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
HU9600050D0 (en) Oligonucleotide modulation of protein kinase c
IL127796A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
IL141866A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU3693697A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU1676699A (en) Human signal transduction serine/threonine kinase
AU6882598A (en) Protein kinase inhibitor
GB2328210B (en) Stabilizer mixture based on polyalkyl-l-oxa-diazaspirodecane compounds
HUP0103079A3 (en) Modulating multiple lineage kinase proteins
GB2341180A9 (en) Compounds on the basis of polyalkyl-1-oxa diazaspirodecane compounds
AU6049399A (en) Serine/threonine protein kinases
AU6421498A (en) Serine/threonine protein kinase
AU6546098A (en) Serine/threonine protein kinase
AU8778698A (en) Serine/threonine kinase, and uses related thereto
GB9803399D0 (en) Protein kinase c
ZA983669B (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds.
AU6770398A (en) Histidine kinase assay

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ZENTARIS GMBH, DE

Free format text: FORMER OWNER(S): ASTA MEDICA AKTIENGESELLSCHAFT, DE; BLITZ F02-570 GMBH, DE; ZENTARIS AG, DE; ZENTARIS GMBH, DE

FC4A Lapse of provisional application due to refusal